Objective-It is suggested that the angiotensin II (Ang II)-Ang II type 1 receptor (AT1R) pathway plays a pivotal role in the pathogenesis of atherosclerosis. Recently, bone marrow (BM) cells were reported to express AT1R. Here, we investigated the role of AT1R in BM in the pathogenesis of atherosclerosis. Methods and Results-Genetic ablation or pharmacological blockade of AT1R led to a significant reduction and stabilization of atherosclerotic lesions in ApoE Ϫ/Ϫ mice. To elucidate the role of AT1R in BM, we generated several BM chimeric mice. Ang II promoted atherosclerosis progression in the BM chimeric mice that had AT1aR in BM, regardless of the absence of AT1aR in the recipient vasculature (PϽ0.05). BM chimeric mice whose BM AT1aR was disrupted showed significantly less atherosclerotic lesions in aorta (PϽ0.05) and more stable plaque with reduced accumulation of BM-derived cells compared with BM chimeric mice that had AT1aR-positive BM. Most of the BM-derived cells in atheroma were positive for a macrophage marker and expressed matrix metalloproteinase (MMP)-9 and monocyte chemoattractant protein-1. Conclusions-Our findings suggest that AT1R in BM plays an important role in the pathogenesis of atherosclerosis.
I
t is a widely accepted view that atherosclerosis is a chronic inflammatory disease. 1 Although multifactorial in etiology, vascular inflammation produces atherosclerosis through the continuous recruitment of circulating leukocytes into the vessel wall and by contributing to an oxidant-rich inflammatory milieu. Recent advances in immunology have dissected several molecular pathways that induce and promote inflammatory responses in atherosclerotic lesions. 1 The renin-angiotensin system (RAS) has been suggested to play a role in the pathogenesis of atherosclerosis by simulating a series of coordinated cellular and molecular events observed in atherosclerotic lesions. 2 Angiotensin II (Ang II) induces the production of reactive oxygen species and stimulates the expression of adhesion molecules and chemokines, leading to endothelial dysfunction, adhesion and invasion of leukocytes, lipid deposition, and smooth muscle cell proliferation. 2 These observations suggest that local effects of an activated RAS in the vessel wall play a central role in the pathogenesis of chronic vascular inflammation by directly acting on resident vascular cells.
The RAS is reported to be involved in the maintenance of cell proliferation and organ remodeling under physiological or pathophysiological conditions in many tissues other than the cardiovascular system. 2 It was suggested that an activated RAS has local effects in bone marrow (BM), which contributes to the regulation of both normal and malignant hematologic processes. 3 It was demonstrated that Ang II increases hematopoietic progenitor cell proliferation. 4 Recently, Cassis et al reported that Ang II promoted vascular pathology via Ang II type 1a receptor (AT1aR) and that AT1aR expressed on infiltrating cells exerted modest regulation of Ang IIinduced atherosclerosis in LDL receptor-deficient mice. 20 It was suggested that the presence of AT1aR in resident tissue was required for the initiation of Ang II-induced atherosclerosis and aneurysm formation.
Although ApoE-deficient and LDL receptor-deficient mice are the most widely used mouse models for atherosclerosis, they differ markedly in lesion type and in their susceptibility to different atherogenic stimuli. 5 Here, we tested the hypothesis that local effects of an activated RAS, especially AT1aR, in BM may play a role in the pathogenesis of atherosclerosis in ApoE-deficient mice. Analyses of BM chimeric mice revealed that AT1aR in BM plays an important role in progression and destabilization of atherosclerotic plaques. We performed a detailed analysis of cellular components of plaque composition and investigated the molecular mechanism by which BM AT1aR contributes to progression and destabilization of atherosclerotic plaque.
Methods Animals
ApoE-deficient (ApoE Ϫ/Ϫ ) mice were originally purchased from Jackson Laboratory. Mice deficient in AT1aR, the type 1a receptor of Ang II, (AT1aR Ϫ/Ϫ ) were described previously. 6 GFP mice were described previously. 7 Double knockout mice deficient in ApoE and AT1aR were generated by cross-breeding ApoE Ϫ/Ϫ mice and AT1aR Ϫ/Ϫ mice. Furthermore, we also generated GFP-positive ApoE Ϫ/Ϫ AT1aR ϩ/ϩ mice (ApoE Ϫ/Ϫ AT1aR ϩ/ϩ GFP ϩ/ϩ mice) and GFPpositive ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice (ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ GFP ϩ/ϩ mice). We administered 10 mg/kg/d olmesartan, an AT1R blocker, or 30 mg/kg/d hydralazine to 6-week-old male ApoE Ϫ/Ϫ mice by gavage every day for 24 weeks. An osmotic mini-pump (Alzet) was used to infuse Ang II (5 mg/kg/d).
Bone Marrow Transplantation
Bone marrow transplantation (BMT) was performed as described previously. 7 At 4 weeks after BMT, all animals were started on a Western type diet. We used only BM chimeric mice, in which more than 80% of BM had been replaced by donor BM. All experimental procedures and protocols were approved by the Animal Care and Use Committee of the University of Tokyo.
Preparation of Aortas and Atherosclerotic Lesions
Lipid deposition was quantified by en face analysis of the aorta as previously described. 8 The atherosclerotic lesions in aortic root were analyzed by Oil red O staining, Sirius red staining, and immunohistochemistry as previously described. 9 
Laser Microdissection and Quantitative Real-Time Polymerase Chain Reaction
The atherosclerotic lesions were collected from the aortic root with a Laser Microdissection System (AS LMD, Leica) according to the manufacturer's instructions. Total RNA was isolated with the use of the RNeasy MicroKit (QIAGEN). First strand cDNA was synthesized from the obtained total RNA using a Quantitect Reverse Transcription Kit (QIAGEN) for quantitative real-time polymerase chain reaction (PCR). Next, we administered 10 mg/kg/d olmesartan (nϭ6), an AT1R blocker, or 30 mg/kg/d hydralazine (nϭ6) to 6-weekold male ApoE Ϫ/Ϫ AT1aR ϩ/ϩ mice fed a Western-type diet every day by gavage for 24 weeks. There was no significant difference between the 2 groups in systolic blood pressure (hydralazine, 64.7Ϯ2.6 versus olmesartan, 61.7Ϯ1.4 mm Hg; Pϭ0.52) or plasma total cholesterol level (hydralazine, 527Ϯ33 versus olmesartan, 523Ϯ27 mg/dL, Pϭ0.93). Consistent with the effects of genetic ablation of AT1aR, en face Sudan IV staining of the aortic arch revealed significant suppression of atherosclerotic lesion progression by olmesartan (2.8Ϯ0.6 versus 5.1Ϯ0.5 mm 2 , Pϭ0.01) ( Figure 1D ). Furthermore, Oil red O staining of the plaques in the aortic root revealed that olmesartan decreased lipid content (7.3Ϯ1.3 versus 14.5Ϯ2.9%, Pϭ0.048) with increased collagen content (38.7Ϯ4.3 versus 23.1Ϯ4.5%, Pϭ0.03) as detected by Sirius red staining.
Statistical Analysis

Effects of Restoration of BM AT1aR on Atherosclerosis in ApoE
To evaluate the potential contribution of AT1aR in BM to the pathogenesis of atherosclerosis, we generated several combinations of BM chimeric mice. We performed BMT from ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice to ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice at 10 to 14 weeks of age. We also performed BMT from ApoE Ϫ/Ϫ recipients with AT1aR Ϫ/Ϫ BM, although atherosclerotic lesion area in aorta (Figure 2 ), lipid content in atheroma and RNA expression in the lesion were similar (supplemental Table I ). Taken together, these results suggest that BM transplantation from AT1aR ϩ/ϩ donors to AT1aR Ϫ/Ϫ recipients could restore Ang II-induced acceleration of atherosclerosis and plaque destabilization. Figure 3A ). In these Figure 3B and 3C) . These results suggest that BM-derived cells may play a role in the pathogenesis of accelerated atherosclerosis induced by Ang II. Infiltration of macrophages into the lesions was significantly reduced in the AT1aR ϩ/ϩ recipients with AT1aR Ϫ/Ϫ BM compared with that in the AT1aR ϩ/ϩ recipient with AT1aR ϩ/ϩ BM as demonstrated by immunostaining for MOMA-2 (11.2Ϯ1.2 versus 17.8Ϯ2.1%, Pϭ0.02; Figure 3D ). MMP-9 RNA expression in the AT1aR ϩ/ϩ recipient with AT1aR Ϫ/Ϫ BM in atheroma was significantly reduced compared with that in the AT1aR Figure 2 ). However, lipid deposition, collagen content, and RNA expression in atheroma were similar in the AT1aR ϩ/ϩ recipients repopulated with AT1aR ϩ/ϩ BM or AT1aR Ϫ/Ϫ BM (supplemental Table I ). To investigate how AT1aR positive BM cells contribute to the pathogenesis of atherosclerosis, we examined gene expression in the plaques by means of a laser microdissection system and quantitative RT-PCR (nϭ4 in each group) at 4 weeks after Ang II infusion ( Figure 4A ). Expressions of MMP-9 (3.0-fold, Pϭ0.04) and MCP-1 (7.1-fold, Pϭ0.02) in the AT1aR ϩ/ϩ recipients repopulated with AT1aR ϩ/ϩ BM was significantly greater than those in the AT1aR ϩ/ϩ recipients repopulated with AT1aR Ϫ/Ϫ BM. On the other hand, there was no significant difference in VCAM-1 expression between the 2 BM chimeric mice. Accumulation of BM-derived GFPpositive cells was significantly accelerated in AT1aR 
Effects of Targeted Disruption of BM AT1aR on
Discussion
In this study, we demonstrated that genetic ablation or pharmacological blockade of AT1R effectively suppressed atherosclerotic lesion formation with more stabilized morphological characteristics of the plaque. We found that functional contribution of the AT1aR in BM to the pathogenesis of atherosclerosis in vivo.
The RAS has been considered to be a circulating hormonal system that regulates blood pressure and flow. Recent studies have provided evidence for local effects of an activated RAS, particularly in the cardiac, vascular, and renal systems. 10 It is now well established that Ang II has significant proinflammatory actions on the vessel wall, leading to progression of atherosclerosis. 11 It is well known that there are 2 different types of Ang II receptors, AT1R and AT2R, in mammals. Both AT1R and AT2R have been identified in the vessel wall. In rodents, 2 AT1R subtypes, AT1aR and AT1bR, have been identified. In the vasculature, AT1aR is predominant and mediates most of the physiological and pathophysiological responses to Ang II in mice. 6 There is increasing evidence of cross-talk between RAS and dyslipidemia in atherogenesis. 12 It was demonstrated that hypercholesterolemia stimulates angiotensin peptide synthesis 12 and increased the density of AT1R, 13 suggesting that Ang II-AT1R pathway may meditate, at least in part, the atherogenic effects of hypercholesterolemia. Consistently, previous reports demonstrated that inhibition of AT1R-signaling reduces atherosclerosis. 14 The greatest AT1R density has been found on vascular smooth muscle cells and endothelial cells. Thus, the antiatherogenic effects of AT1R blockade are thought to result from inhibition of AT1R-mediated signaling in resident vascular cells.
Recent reports suggest that local effects of an activated RAS exist in BM and functions to promote differentiation and proliferation of BM cells. 4 Our preliminary study revealed that AT1aR was abundantly expressed in BM, whereas other receptors were hardly detected (supplemental Figure IA) . We also found that AT1aR could be detected in atherosclerotic lesions in the AT1aR Ϫ/Ϫ recipients repopulated with AT1aR ϩ/ϩ BM (supplemental Figure IB) . Thus, we here focused on AT1aR in BM, although it is plausible that other receptors of Ang II may participate in the atherogenic effects of Ang II.
Previous reports have demonstrated that AT1R in the vasculature mediates upregulation of adhesion molecules and chemokines, thus promoting infiltration of inflammatory cells into the vessel wall. 15 MCP-1 in vascular cells is one of the essential inflammatory mediators in Ang II-induced progression of atherosclerosis. 16 Several reports have demonstrated that monocytes/macrophages release MCP-1 through activation of the Ang II-AT1R pathway in vitro. 17 mice that received Ang II infusion for 4 weeks. It was suggested that AT1aR-positive BM-derived cells themselves could be a source of MCP-1 in plaques. As well as MCP-1, MMPs are demonstrated to be expressed in atherosclerotic lesions. 18 Especially, MMP-9 is important for the resorption of extracellular matrix and contributes to progression and destabilization of atherosclerosis. An AT1R antagonist is reported to inhibit MMP-9 expression in a mouse model of atherosclerosis. 19 Our present results showed that AT1aR-positive BM-derived cells are an important source of MMP-9.
Recently, when this study was being conducted, Cassis et al reported that Ang II (1.0 g/kg/min) promotes vascular pathology via AT1aR in LDL receptor-deficient mice. 20 Consistent with our findings, repopulation of AT1aR ϩ/ϩ mice with AT1aR
Ϫ/Ϫ BM resulted in modest reductions in Ang II-induced atherosclerosis. 20 Here, we confirm the importance of AT1aR in BM. In addition, we demonstrate that AT1aR-positive BM cells not only accelerate accumulation of BM-derived cells in the lesions through MCP-1 expression, but also contribute to plaque progression and destabilization by secretion of MMP-9, at least in part. Thus, our study significantly extends the findings of Cassis et al and provides novel insights into the mechanism by which Ang II promotes atherosclerosis progression and instability.
Unexpectedly, Cassis et al found that AT1aR Ϫ/Ϫ recipient mice were dramatically protected from Ang II (1.44 mg/kg/d for 4 weeks)-induced vascular pathologies irrespective of BM donor genotype, suggesting that the presence of AT1aR in resident tissue is required for the initiation of Ang II-induced atherosclerosis. 20 In this study, we also found that atherosclerosis development was notably retarded in AT1aR Ϫ/Ϫ recipients with vehicle infusion regardless of the existence of AT1aR in BM. However, Ang II infusion at a higher dose for a longer period (5.0 mg/kg/d for 8 weeks) could promote atherosclerosis significantly even in AT1aR Ϫ/Ϫ recipients when the BM cells were repopulated with AT1aR ϩ/ϩ BM. Others reported that there are several differences in the pathogenesis of dyslipidemia and atherosclerosis between ApoE Ϫ/Ϫ and LDL-R Ϫ/Ϫ mice. 5 Moreover, we infused Ang II into BM chimeric mice at 12 weeks after BMT, whereas Cassis et al started Ang II treatment at 7 weeks after BMT. In our study, blood cell count at 12 weeks after BMT was similar among 4 BMT groups. At 40 weeks after BMT, the blood cell count and the BM cell composition were also similar in the AT1aR ϩ/ϩ recipients repopulated with AT1aR ϩ/ϩ BM and AT1aR Ϫ/Ϫ BM (supplemental Table II ). However, many reports documented that only the limited number of engrafted cells are matured with skewed population frequencies at 4 to 6 weeks after BMT, although high numbers of donor cells can be observed in peripheral blood at 4 to 6 weeks after BMT. 21 Assays of immune function indicate deficient functions at earlier time points after BMT. Thus, the differences in the type of hypercholesterolemic mice, the protocol of Ang II infusion, and the timing of Ang II infusion relative to the BMT might lead to the different results by us and by Cassis et al.
The dose of Ang II used in our study might be high compared with those used in previous studies. However, 5 mg/kg/d Ang II did not cause apparent toxic effects, such as increased mortality (supplemental Table III) , changes in plasma lipid profile, or body weight loss, in the BM chimeric mice. Moreover, in our preliminary study, 3.0 mg/kg/d of Ang II infusion was not sufficient for blood pressure elevation and acceleration of atherosclerosis even in AT1aR ϩ/ϩ recipients repopulated with AT1aR ϩ/ϩ BM (Fukuda and Sata, unpublished data), suggesting that higher dose of Ang II would be required to evaluate the effects of Ang II in BM chimeric ApoE Ϫ/Ϫ mice repopulated with exogenous BM after lethal irradiation. Therefore, we chose the dose of 5 mg/kg/d of Ang II in this study.
Unexpectedly, in our study, ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice showed significantly higher total cholesterol level than that in ApoE Ϫ/Ϫ AT1aR ϩ/ϩ mice. This was inconsistent with previous reports. 22 Analysis of lipid profile showed similar pattern in ApoE Ϫ/Ϫ AT1aR ϩ/ϩ mice and ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice (data not shown). ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice showed significantly lower blood pressure compared with ApoE Ϫ/Ϫ AT1aR ϩ/ϩ mice, consistent with a previous report. 22 It could be possible that alteration of blood pressure and lipid level may affect the development of atherosclerosis in ApoE Ϫ/Ϫ AT1aR Ϫ/Ϫ mice. However, in our experiment on pharmacological blockade of AT1R, there were no significant difference in blood pressure and cholesterol level between olmesartan-treated mice and hydralazine-treated mice. In our studies with BM chimeric mice, there was no significant difference in blood pressure or plasma cholesterol level in AT1aR Ϫ/Ϫ recipients or AT1aR ϩ/ϩ recipients regardless of BM AT1aR genotype. Therefore, our data obtained with the BM chimeric mice appear to be independent of blood pressure and plasma cholesterol level. In summary, our results suggest that AT1aR expressed not only on vascular cells but also on BM-derived cells plays a role in the pathogenesis of atherosclerosis, at least in part. Therefore, blockade of AT1R not only in vascular cells but also in BM could be an important strategy to prevent the progression and destabilization of atherosclerotic plaques.
